Search | Clinical Trials Finder

Conditions: Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell, Non Small Cell Lung Cancer Metastatic
Interventions: Nivolumab, Ipilimumab, Nintedanib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions: APX005M, Cabiralizumab, Nivolumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Retifanlimab, Tuparstobart, Verzistobart; Procedure · Biological · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Urothelial Carcinoma
Interventions: Atezolizumab, Bevacizumab; Drug
Lead sponsor: Arjun Balar, MD; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Phoenix, Arizona • Chicago, Illinois • Minneapolis, Minnesota + 4 more

Conditions: Non Small Cell Lung Cancer
Interventions: Gotistobart, Docetaxel; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 46
States / cities: Dothan, Alabama • Russellville, Arkansas • Cerritos, California + 42 more

Conditions: Cancer
Interventions: 5-FU, Atezolizumab, Bevacizumab, Carboplatin, Leucovorin, Nab-paclitaxel, Oxaliplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 11
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Melanoma
Interventions: Belvarafenib, Cobimetinib, Nivolumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Conditions: Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIC Lung Cancer AJCC v8
Interventions: Carboplatin, Durvalumab, Gemcitabine, Local Consolidation Therapy, Nab-paclitaxel, Paclitaxel, Pemetrexed, Quality-of-Life Assessment, Questionnaire Administration; Drug · Biological · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions: Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Miami, Florida • Tampa, Florida + 20 more

Conditions: Non Small Cell Lung Carcinoma NSCLC
Interventions: Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Neoplasms, Head and Neck
Interventions: feladilimab, Pembrolizumab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 13
States / cities: Duarte, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 10 more

Conditions: Refractory Metastatic Colorectal Cancer, pMMR, MSS
Interventions: RP2, RP3, atezolizumab, bevacizumab; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Seattle, Washington

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: Nivolumab, Sitravatinib, Docetaxel; Biological · Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab; Dietary Supplement · Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 350
States / cities: Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: MEDI4736, Tremelimumab, MEDI4736+Tremelimumab, Cetuximab, 5-fluorouracil (5FU), Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 823 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 19
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 14 more

Conditions: Neoplasms
Interventions: feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
Interventions: Atezolizumab, Bevacizumab; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Carcinoma, Hepatocellular
Interventions: Atezolizumab, Bevacizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 5 more

Conditions: Renal Cell Carcinoma
Interventions: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 25
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung, Lung Cancer, Squamous Cell Lung Cancer
Interventions: Docetaxel, Nivolumab, Gemcitabine, Pemetrexed; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Anderson, Indiana • Indianapolis, Indiana • Muncie, Indiana + 4 more

Conditions: Merkel Cell Carcinoma, Small Cell Lung Cancer
Interventions: XmAb18087, XmAb18087 ± Pembrolizumab; Biological · Drug
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Lebanon, New Hampshire + 3 more

Conditions: Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 19
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more

Conditions: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions: AU-007, Aldesleukin, Avelumab, Nivolumab; Drug
Lead sponsor: Aulos Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 8 more

Conditions: Metastatic Pancreatic Cancer
Interventions: Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Evaluating Novel Therapies in ctDNA Positive GI Cancers

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.